Minerva Neurosciences, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Minerva Neurosciences, Inc. (NERV) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $31.32 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-03
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $31.32M.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$23.87K.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$79.80M, a 1052.81% decline year-over-year.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$10.89M, a 877.78% decline year-over-year.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$107.19M, a 701.57% decline from fiscal 2016.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $17.82M.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$18.33M, a 1785.87% decline from fiscal 2014.
- Minerva Neurosciences, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $1.09M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $31.32M 10-Q · filed 2018-05-03 | $31.29M derived: sum of 2 quarters · filed 2018-05-03 | -$48.51M derived: sum of 3 quarters · filed 2018-05-03 | -$59.40M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | -$23.87K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$79.82M derived: sum of 2 quarters · filed 2018-03-12 | -$90.71M derived: sum of 3 quarters · filed 2018-03-12 | -$107.19M 10-K · filed 2018-03-12 |
| 2017-09-30 | -$79.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | -$90.69M derived: sum of 2 quarters · filed 2017-11-06 | -$107.16M 10-Q · filed 2017-11-06 | -$107.16M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | -$10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$27.37M 10-Q · filed 2017-08-03 | -$27.37M derived: sum of 3 quarters · filed 2018-05-03 | -$18.99M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | -$16.48M 10-Q · filed 2018-05-03 | -$16.48M derived: sum of 2 quarters · filed 2018-05-03 | -$8.10M derived: sum of 3 quarters · filed 2018-05-03 | -$6.70M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $8.38M derived: sum of 2 quarters · filed 2018-03-12 | $9.78M derived: sum of 3 quarters · filed 2018-03-12 | $17.82M 10-K · filed 2018-03-12 |
| 2016-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $9.78M derived: sum of 2 quarters · filed 2017-11-06 | $17.82M 10-Q · filed 2017-11-06 | $21.87M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $9.44M 10-Q · filed 2017-08-03 | $13.49M derived: sum of 3 quarters · filed 2018-03-12 | $14.32M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $8.04M 10-Q · filed 2017-05-04 | $12.09M derived: sum of 2 quarters · filed 2018-03-12 | $12.92M derived: sum of 3 quarters · filed 2018-03-12 | -$10.28M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $4.88M derived: sum of 2 quarters · filed 2018-03-12 | -$18.32M derived: sum of 3 quarters · filed 2018-03-12 | -$18.33M 10-K · filed 2018-03-12 |
| 2015-09-30 | $827.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$22.37M derived: sum of 2 quarters · filed 2016-11-03 | -$22.38M 10-Q · filed 2016-11-03 | -$22.43M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | -$23.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$23.21M 10-Q · filed 2016-08-04 | -$23.25M derived: sum of 3 quarters · filed 2017-03-13 | -$23.29M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | -$4.99K 10-Q · filed 2016-05-03 | -$51.87K derived: sum of 2 quarters · filed 2017-03-13 | -$85.61K derived: sum of 3 quarters · filed 2017-03-13 | -$85.61K derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | -$46.88K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$80.62K derived: sum of 2 quarters · filed 2017-03-13 | -$80.62K derived: sum of 3 quarters · filed 2017-03-13 | $1.09M 10-K · filed 2017-03-13 |
| 2014-09-30 | -$33.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$33.74K derived: sum of 2 quarters · filed 2015-11-05 | $1.13M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.17M 10-Q · filed 2015-08-05 | ||
| 2014-03-31 | $1.17M 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | -$3.23K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |